33 results about "Hypoparathyroidism" patented technology

Novel parathyroid hormone polypeptides and biologically active fragments thereof are disclosed along with nucleic acid molecules encoding same. In particular, parathyroid hormone polypeptides and biologically active fragments (and encoding nucleic acid molecules) derived from fish species (eg Japanese pufferfish (Fugu rubripes)) are disclosed. Such polypeptides and fragments may be used for treatment of diseases associated with abnormal calcium homeostasis (eg osteoporosis, osteopenia, Paget's disease, bone cancer, hyperparathyroidism, hypoparathyroidism, hypercalcemia, psoriasis and other skin-related conditions).

Disclosed are two PTH analog ligands, SP-PTH-AAK and Aib-SP-PTH-AAK, that have long-acting activity at the PTH receptor, as demonstrated both in vitro and in vivo. These polypeptides are thus particularly useful in the treatment of diseases, such as hypoparathyroidism, in which long-acting activity is desired. The method of making the analog polypeptides is also disclosed.

The invention relates to parathyroid hormone (PTH) variants and pharmaceutical compositions comprising same. The invention further relates to PTH compositions with improved serum half-life and peak-trough ratios, and methods of controlling serum calcium levels with the PTH variants and compositions of the invention. The invention further relates to methods of treating hypoparathyroidism and / or hypocalcemia due to hypoparathyroidism with the PTH variants and compositions of the invention.

The invention discloses a glycoside enrichment of Ligustrum lucidum, the preparation method of which comprises the following steps: adding 10-14 times of ethanol with a volume concentration of 50-80% to Ligustrum lucidum, refluxing and extracting for 1-3h, filtering, and Add 8 times the amount of ethanol with a volume concentration of 50-80% to the residue, reflux for extraction for 1-3 hours, filter, combine the two filtrates, recover the solvent, add an appropriate amount of ethyl acetate for extraction, discard the ethyl acetate layer, and add water to the water layer to saturate Extract with n-butanol, combine the water-saturated n-butanol layers, concentrate, and vacuum-dry to obtain the glycoside enrichment of Ligustrum lucidum. The invention also discloses the application of the Ligustrum lucidum glucoside enrichment in the preparation of medicine for treating hypoparathyroidism.

The sulfoneamide compounds having the following Formula (1), which can be used as an effective component of a CaSR antagonizing agent useful for prophylaxis and / or treatment of bone disorders including osteoporosis and etc., are provided. The compounds have an excellent activity of promoting PTH secretion. In addition, the compounds are useful as an effective component of a medicament for the prophylaxis and / or treatment of bone disorders such as osteoporosis, bone fracture, hypoparathyroidism and the like.

The present invention relates to peptides that are parathyroid hormone (PTH) analogs, useful for the treatment of hypoparathyroidism and diseases characterized by bone mass reduction, such as osteoporosis, and for stimulating bone repair or favoring the engraftment of a bone implant; to the pharmaceutical compositions comprising these PTH-like peptides and use thereof.

Described are polypeptide analogs of parathyroid hormone (PTH) that include an unnatural amino acid substitution at positions 7 or 8 from the N-terminus of the polypeptide. Also described are pharmaceutical compositions useful for treating hypoparathyroidism that contain the analogs and methods of using the analogs to treat hypoparathyroidism.

The disclosure relates to long acting parathyroid or parathyroid hormone like fusion polypeptides comprising a receptor polypeptide and its use in the treatment of hypoparathyroidism and osteoporosis.